NDASUBLINGUALFILM
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
CASSIPA (buprenorphine hydrochloride; naloxone hydrochloride) by Teva is naloxone. First approved in 2018.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CASSIPA is a sublingual film combination of buprenorphine (partial mu-opioid agonist) and naloxone (opioid antagonist) approved in 2018 for opioid use disorder treatment. The naloxone component deters misuse by inducing withdrawal if the product is injected, while buprenorphine provides maintenance therapy. This formulation addresses a critical public health need in addiction medicine.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30% intensity), indicating stable team headcount and focus on market defense rather than growth expansion.
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.
Started Jan 2020
0Evaluation of QTc Interval
Career Relevance
Working on CASSIPA offers exposure to opioid use disorder therapeutics in a stable, peak-stage product with entrenched market position and formulary leverage. Roles emphasize defensive market share management, prescriber relations, and payer negotiation rather than launch dynamics.
Brand Manager
Worked on CASSIPA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.